Last reviewed · How we verify
NCT05166213: PATOLP
Patients' Attitudes Towards Open-Label Placebo Implementation Into Clinical Practice
trial testing focus group discussions (FGD) in Open-label Placebos in 6 participants. Completed in 10 November 2022.
10 November 2022
Quick facts
| Lead sponsor | University Hospital, Basel, Switzerland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6 |
| Start date | 16 December 2021 |
| Primary completion | 10 November 2022 |
| Estimated completion | 10 November 2022 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- focus group discussions (FGD)
Conditions studied
- Open-label Placebos — all drugs for Open-label Placebos →
Sponsor
University Hospital, Basel, Switzerland
Who can join
18 and older, any sex, with Open-label Placebos. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this project is to assess patients' opinions, attitudes, and ideas regarding the administration of OLPs in clinical practice, although they might never have had contact to placebos. A qualitative approach is used and online focus group discussions (FGD) with patients with different clinical conditions, entailing chronic back pain, Parkinson's disease, chronic migraine, chemotherapy induced emesis, and menopausal complaints are conducted.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Talking placebo: a qualitative study of patients' attitudes toward open-label placebo implementation into clinical practice.
Frey Nascimento A, Bakis B, Gaab J, Schneider T, et al · · 2025 · PMID 40823423 · DOI 10.3389/fpsyg.2025.1533663
Verify or expand the search:
- PubMed search for NCT05166213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Basel, Switzerland trials
Trials by the same sponsor.
- NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
- NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
- NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
- NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
- NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05166213 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
- Last refreshed: 17 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing